Imlifidase (also known as Idefirix and made by Hansa Biopharma) has been recommended for people who are waiting for a kidney ...
NICE’s final draft guidance recommends abemaciclib (also called Verzenios and made by Eli Lilly) for people with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high ...
NICE medical technologies guidance addresses specific technologies notified to NICE by companies. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology ...
Pembrolizumab is used with chemotherapy in adults with triple negative breast cancer whose tumours express PD-L1 with a combined positive score (CPS - the number of PD-L1 positive cells in relation to ...
Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has ...
Thousands of people in England could benefit after NICE today (Tuesday, 24 May) published final draft guidance recommending a new drug to help treat two leading causes of sight loss and visual ...
NICE is unable to make a recommendation on anifrolumab (Saphnelo) for active autoantibody-positive systemic lupus erythematosus. This is because AstraZeneca did not provide an evidence submission. We ...
Cognitive behavioural therapy to manage symptoms associated with the menopause. Interventions to manage genitourinary symptoms associated with the menopause. Effects of hormone replacement therapy on ...
This guidance updates and replaces NICE technology appraisal guidance 491 on ibrutinib for treating Waldenstrom’s macroglobulinaemia, which was available through the Cancer Drugs Fund. People already ...
There is a simple discount patient access scheme for diroximel fumarate. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...
NICE has developed a medtech innovation briefing (MIB) on TriageHF Plus for remotely monitoring people with cardiac implantable electronic devices at risk of heart failure or worsening heart failure.